chartexchange

CLRB
Cellectar Biosciences INC NEW
stockNASDAQ

At CloseNov 18, 2026 3:59:30 PM EST
0.8803USD-4.346%(-0.04)50,166
Pre-marketNov 18, 2026 8:39:30 AM EST
0.9199USD-0.043%(-0.0004)
After-hoursNov 18, 2026 4:00:30 PM EST
0.8852USD+0.557%(+0.0049)
Loading…
Loading…
Healthcare
Biotechnology
CEO
James Caruso
HQ
Florham Park, NJ, USA
Previous Close
$0.92
Beta
1.64
52-Week High
$4.70 2026-05-05
52-Week Low
$0.88 2026-11-18
SMA 50
$1.54
SMA 200
$2.48
Avg. Vol 10D
75,865
Avg. Vol 30D
143,281
Avg. Vol 90D
88,683
Relative Vol
0.35
9.86M
7.8600%
1,190
Jun 24, 2025 · 1-for-30 (reverse)
CLRB Profile

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p

CLRB Performance
PeriodPriceDateChangeBeta
1W1.162026-11-12-24.13%5.599
1M1.122026-10-19-21.42%1.869
3M2.622026-08-19-66.41%1.381
6M3.062026-05-19-71.24%1.523
1Y2.862025-11-19-69.23%1.636
2Y48.302024-11-19-98.18%—
5Y226.502021-11-19-99.61%1.175
CLRB Stock Summary

Cellectar Biosciences INC NEW (NASDAQ:CLRB) stock price today is $0.88, and today's volume is 50,166. CLRB is down 4.368% today. The 30 day average volume is 143,281. CLRB market cap is $8.84M with 10.04M shares outstanding.